MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/550/0.01/20.12.24

MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/550/0.01/20.12.24 Stock

DE000ME6HRB3

Real-time Bid/Ask 10:58:29 2024-07-04 EDT
0.141 ^EUR / 0.159 ^EUR	+7.14%

Current month	-11.95%
1 month	-20.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/550/0.01/20.12.24

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

FDA Accepts Vertex Pharmaceuticals' New-Drug Application for Combination Therapy to Treat Cystic Fibrosis	07-02	MT
Vertex Gets Speedy FDA Review of Vanza Triple Cystic Fibrosis Therapy	07-02	DJ
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis	07-02	BU
Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, A Next-In-Class Triple Combination Treatment for Cystic Fibrosis	07-02	CI

More news

Quotes 5-day view

Date	Price	Change
24-07-04	0.141	+0.71%
24-07-03	0.14	-9.09%
24-07-02	0.154	+2.67%
24-07-01	0.15	-5.66%
24-06-28	0.159	-0.63%

Delayed Quote Börse Stuttgart

Last update July 04, 2024 at 10:27 am

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	Morgan Stanley
WKN	ME6HRB
ISIN	DE000ME6HRB3
Date issued	2024-01-05
Strike	550 $
Maturity	2024-12-20 (169 Days)
Parity	100 : 1
Emission price	0.15 €
Emission volume	N/A
Settlement	Por diferencias
Currency	EUR

Technical Indicators

Highest since issue	0.226 €
Lowest since issue	0.074 €
Delta	0.3x
Omega	8.569
Premium	20.4x
Gearing	29.03x
Moneyness	0.8551
Difference Strike	79.72 $
Difference Strike %	+14.49%
Spread	0.018 €
Spread %	11.32%
Theoretical value	0.1490
Implied Volatility	30.06 %
Total Loss Probability	77.19 %
Intrinsic value	0.000000
Present value	0.1490
Break even	566.10 €
Theta	-0.01x
Vega	0.01x
Rho	0.01x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

470.3 USD

Average target price

468.3 USD

Spread / Average Target

-0.43%

Consensus